Evolus, Inc. (NASDAQ:EOLS) Receives Average Rating of “Moderate Buy” from Analysts

Evolus, Inc. (NASDAQ:EOLS) has received a consensus rating of “Moderate Buy” from the six research firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $16.00.

Several equities analysts have weighed in on EOLS shares. Weiss Ratings raised Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday. Mizuho set a $15.00 price objective on Evolus in a report on Wednesday, February 4th. BTIG Research reiterated a “buy” rating and set a $13.00 price objective on shares of Evolus in a report on Wednesday, March 4th. Wall Street Zen downgraded Evolus from a “buy” rating to a “hold” rating in a research note on Sunday, March 15th. Finally, HC Wainwright cut their price objective on Evolus from $20.00 to $13.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd.

Insider Buying and Selling

In other news, insider Rui Avelar sold 29,996 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $4.89, for a total value of $146,680.44. Following the completion of the sale, the insider directly owned 430,542 shares of the company’s stock, valued at $2,105,350.38. This trade represents a 6.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider David Moatazedi sold 13,669 shares of the firm’s stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $4.75, for a total value of $64,927.75. Following the completion of the sale, the insider directly owned 604,700 shares of the company’s stock, valued at approximately $2,872,325. The trade was a 2.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 163,504 shares of company stock valued at $797,184. Insiders own 5.00% of the company’s stock.

Institutional Trading of Evolus

Hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Evolus by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock valued at $400,000 after acquiring an additional 1,838 shares in the last quarter. Millennium Management LLC increased its stake in shares of Evolus by 1.7% in the 1st quarter. Millennium Management LLC now owns 1,392,028 shares of the company’s stock valued at $16,746,000 after purchasing an additional 23,605 shares during the last quarter. Jones Financial Companies Lllp bought a new position in shares of Evolus in the 1st quarter valued at $158,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Evolus by 36.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,565 shares of the company’s stock valued at $1,883,000 after purchasing an additional 41,513 shares during the last quarter. Finally, Jane Street Group LLC increased its stake in shares of Evolus by 484.8% in the 1st quarter. Jane Street Group LLC now owns 69,947 shares of the company’s stock valued at $841,000 after purchasing an additional 57,987 shares during the last quarter. 90.69% of the stock is owned by institutional investors and hedge funds.

Evolus Trading Down 1.2%

EOLS opened at $6.50 on Friday. The stock has a market cap of $428.09 million, a PE ratio of -9.70 and a beta of 1.28. Evolus has a 1 year low of $3.86 and a 1 year high of $10.62. The stock’s 50 day simple moving average is $5.04 and its 200-day simple moving average is $5.62.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The business had revenue of $73.14 million during the quarter, compared to analysts’ expectations of $72.52 million. During the same quarter last year, the business earned ($0.30) EPS. Equities analysts forecast that Evolus will post -0.41 earnings per share for the current fiscal year.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.